Cargando…

Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection

Antibody-mediated rejection (AMR) causes more than 50% of late kidney graft losses. In addition to anti-human leukocyte antigen (HLA) donor-specific antibodies, antibodies against non-HLA antigens are also linked to AMR. Identifying key non-HLA antibodies will improve our understanding of AMR. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Clotet-Freixas, Sergi, Kotlyar, Max, McEvoy, Caitriona M., Pastrello, Chiara, Rodríguez-Ramírez, Sonia, Farkona, Sofia, Cardinal, Heloise, Dieudé, Mélanie, Hébert, Marie-Josée, Li, Yanhong, Famure, Olusegun, Chen, Peixuen, Kim, S. Joseph, Chan, Emilie, Jurisica, Igor, John, Rohan, Chruscinski, Andrzej, Konvalinka, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454907/
https://www.ncbi.nlm.nih.gov/pubmed/34557585
http://dx.doi.org/10.1097/TXD.0000000000001215
_version_ 1784570571027120128
author Clotet-Freixas, Sergi
Kotlyar, Max
McEvoy, Caitriona M.
Pastrello, Chiara
Rodríguez-Ramírez, Sonia
Farkona, Sofia
Cardinal, Heloise
Dieudé, Mélanie
Hébert, Marie-Josée
Li, Yanhong
Famure, Olusegun
Chen, Peixuen
Kim, S. Joseph
Chan, Emilie
Jurisica, Igor
John, Rohan
Chruscinski, Andrzej
Konvalinka, Ana
author_facet Clotet-Freixas, Sergi
Kotlyar, Max
McEvoy, Caitriona M.
Pastrello, Chiara
Rodríguez-Ramírez, Sonia
Farkona, Sofia
Cardinal, Heloise
Dieudé, Mélanie
Hébert, Marie-Josée
Li, Yanhong
Famure, Olusegun
Chen, Peixuen
Kim, S. Joseph
Chan, Emilie
Jurisica, Igor
John, Rohan
Chruscinski, Andrzej
Konvalinka, Ana
author_sort Clotet-Freixas, Sergi
collection PubMed
description Antibody-mediated rejection (AMR) causes more than 50% of late kidney graft losses. In addition to anti-human leukocyte antigen (HLA) donor-specific antibodies, antibodies against non-HLA antigens are also linked to AMR. Identifying key non-HLA antibodies will improve our understanding of AMR. METHODS. We analyzed non-HLA antibodies in sera from 80 kidney transplant patients with AMR, mixed rejection, acute cellular rejection (ACR), or acute tubular necrosis. IgM and IgG antibodies against 134 non-HLA antigens were measured in serum samples collected pretransplant or at the time of diagnosis. RESULTS. Fifteen non-HLA antibodies were significantly increased (P < 0.05) in AMR and mixed rejection compared with ACR or acute tubular necrosis pretransplant, and 7 at diagnosis. AMR and mixed cases showed significantly increased pretransplant levels of IgG anti-Ro/Sjögren syndrome-antigen A (SS-A) and anti-major centromere autoantigen (CENP)-B, compared with ACR. Together with IgM anti-CENP-B and anti-La/SS-B, these antibodies were significantly increased in AMR/mixed rejection at diagnosis. Increased IgG anti-Ro/SS-A, IgG anti-CENP-B, and IgM anti-La/SS-B were associated with the presence of microvascular lesions and class-II donor-specific antibodies (P < 0.05). Significant increases in IgG anti-Ro/SS-A and IgM anti-CENP-B antibodies in AMR/mixed rejection compared with ACR were reproduced in an external cohort of 60 kidney transplant patients. CONCLUSIONS. This is the first study implicating autoantibodies anti-Ro/SS-A and anti-CENP-B in AMR. These antibodies may participate in the crosstalk between autoimmunity and alloimmunity in kidney AMR.
format Online
Article
Text
id pubmed-8454907
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-84549072021-09-22 Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection Clotet-Freixas, Sergi Kotlyar, Max McEvoy, Caitriona M. Pastrello, Chiara Rodríguez-Ramírez, Sonia Farkona, Sofia Cardinal, Heloise Dieudé, Mélanie Hébert, Marie-Josée Li, Yanhong Famure, Olusegun Chen, Peixuen Kim, S. Joseph Chan, Emilie Jurisica, Igor John, Rohan Chruscinski, Andrzej Konvalinka, Ana Transplant Direct Kidney Transplantation Antibody-mediated rejection (AMR) causes more than 50% of late kidney graft losses. In addition to anti-human leukocyte antigen (HLA) donor-specific antibodies, antibodies against non-HLA antigens are also linked to AMR. Identifying key non-HLA antibodies will improve our understanding of AMR. METHODS. We analyzed non-HLA antibodies in sera from 80 kidney transplant patients with AMR, mixed rejection, acute cellular rejection (ACR), or acute tubular necrosis. IgM and IgG antibodies against 134 non-HLA antigens were measured in serum samples collected pretransplant or at the time of diagnosis. RESULTS. Fifteen non-HLA antibodies were significantly increased (P < 0.05) in AMR and mixed rejection compared with ACR or acute tubular necrosis pretransplant, and 7 at diagnosis. AMR and mixed cases showed significantly increased pretransplant levels of IgG anti-Ro/Sjögren syndrome-antigen A (SS-A) and anti-major centromere autoantigen (CENP)-B, compared with ACR. Together with IgM anti-CENP-B and anti-La/SS-B, these antibodies were significantly increased in AMR/mixed rejection at diagnosis. Increased IgG anti-Ro/SS-A, IgG anti-CENP-B, and IgM anti-La/SS-B were associated with the presence of microvascular lesions and class-II donor-specific antibodies (P < 0.05). Significant increases in IgG anti-Ro/SS-A and IgM anti-CENP-B antibodies in AMR/mixed rejection compared with ACR were reproduced in an external cohort of 60 kidney transplant patients. CONCLUSIONS. This is the first study implicating autoantibodies anti-Ro/SS-A and anti-CENP-B in AMR. These antibodies may participate in the crosstalk between autoimmunity and alloimmunity in kidney AMR. Lippincott Williams & Wilkins 2021-09-20 /pmc/articles/PMC8454907/ /pubmed/34557585 http://dx.doi.org/10.1097/TXD.0000000000001215 Text en Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Kidney Transplantation
Clotet-Freixas, Sergi
Kotlyar, Max
McEvoy, Caitriona M.
Pastrello, Chiara
Rodríguez-Ramírez, Sonia
Farkona, Sofia
Cardinal, Heloise
Dieudé, Mélanie
Hébert, Marie-Josée
Li, Yanhong
Famure, Olusegun
Chen, Peixuen
Kim, S. Joseph
Chan, Emilie
Jurisica, Igor
John, Rohan
Chruscinski, Andrzej
Konvalinka, Ana
Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection
title Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection
title_full Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection
title_fullStr Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection
title_full_unstemmed Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection
title_short Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients With Kidney Allograft Antibody-mediated Rejection
title_sort increased autoantibodies against ro/ss-a, cenp-b, and la/ss-b in patients with kidney allograft antibody-mediated rejection
topic Kidney Transplantation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454907/
https://www.ncbi.nlm.nih.gov/pubmed/34557585
http://dx.doi.org/10.1097/TXD.0000000000001215
work_keys_str_mv AT clotetfreixassergi increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT kotlyarmax increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT mcevoycaitrionam increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT pastrellochiara increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT rodriguezramirezsonia increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT farkonasofia increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT cardinalheloise increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT dieudemelanie increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT hebertmariejosee increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT liyanhong increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT famureolusegun increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT chenpeixuen increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT kimsjoseph increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT chanemilie increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT jurisicaigor increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT johnrohan increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT chruscinskiandrzej increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection
AT konvalinkaana increasedautoantibodiesagainstrossacenpbandlassbinpatientswithkidneyallograftantibodymediatedrejection